TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Stress response (cortisol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stress response (systolic blood pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stress response (diastolic blood pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stress response (heart rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Agitation scale ratings (Behavioral Activity Rating Scale)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Change in HCV-RNA Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular microbial flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histological quality of the EMR specimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of new gadolinium-enhancing lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Current proportion of mature men presenting for and undergoing MMC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Count of Participants With Mature Arteriovenous Fistula (AVF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Students' interest in studying anatomy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in TMAO level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to scar formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Median time to termination of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of Iowa Infant Feeding Attitude Scale (IIFAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes of Breastfeeding Self-Efficacy Scale-Short Form (BSES-SF)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes of Maternal Attachment Inventory (MAI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in average glycemic control (A1C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline of the QTcI interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tear Film thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PROMIS 29 scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total Nasal Symptom Score as Measured by the Visual Analog Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Wound Size - Length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in Wound Size - Width
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in Wound Size - Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Head Movements During Rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertical depth of recession
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve for Ivermectin and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration for Ivermectin and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximum concentration for Ivermectin and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall-survival time
Endpoint domain: Mortality/survival
Primary endpoint: Compartment Specific Knee Minimum Joint Space Width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: susceptibility genes localization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of school children with overjet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PGE2 biosynthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Hamilton Depression Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area Under the Concentration Time Curve (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain oxygen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Peripheral measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Drug Related Adverse Events or Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Myocardial FDG Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in working memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cannabis Craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's emergency room visits/hospitalizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's language development at 21 months
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in worry
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Operational taxonomic units
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NAFLD and significant fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Fractional Area Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Photoparoxysmal response (PPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Standardized photoparoxysmal response (SPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: LDL-C (% change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change of HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change Assessment of Pain of OLP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change Thongprasom sign scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Number of incidents of challenging behaviour
Endpoint domain: Adverse events/effects
Primary endpoint: Drug Measurement of MPA and MPA-G
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IMPDH Assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mitogenesis Assays
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Determination of CD25 Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tactile pain thresholds adjacent to the surgical wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With 1st Uptake Shots
Endpoint domain: Mortality/survival
Primary endpoint: Mean Level of 25(OH)D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence and severity of rash development
Endpoint domain: Adverse events/effects
Primary endpoint: Systolic and Diastolic blood pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: risk of breast cancer development
Endpoint domain: Mortality/survival
Primary endpoint: Change in total serum 25D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety and tolerability of MSC-1
Endpoint domain: Adverse events/effects
Primary endpoint: Preliminary anti-tumor activity of MSC-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: PCT frequency of the eye affected by optic neuritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: British Isles Lupus Assessment Group score (BILAG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of CL-108
Endpoint domain: Adverse events/effects
Primary endpoint: Balance Measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait Measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiration rate measurement accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Alcohol Use Disorders Identification Test (AUDIT) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of Target Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphine consumption in the first 48 hours post-surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of the PET/CT synchronized exam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-mullerian Hormone (AMH) Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Concentration of nitric oxide in exhaled breath
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: composite risk of death
Endpoint domain: Mortality/survival
Primary endpoint: cardiac arrest
Endpoint domain: Mortality/survival
Primary endpoint: syncope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Induction mortality
Endpoint domain: Mortality/survival
Primary endpoint: Urine toxicology for cocaine
Endpoint domain: Adverse events/effects
Primary endpoint: Stair Time up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-peptide Response to Mixed Meal Glucose Tolerance Test (MMTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Amount of dendritic cell-derived exosomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of major and minor hypoglycaemic events
Endpoint domain: Adverse events/effects
Primary endpoint: 6-year progression rate of subclinical atherosclerotic disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Long-term quality of life at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Long-term quality of life at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hair mineral levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in MARP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum triglyceride concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum serum triglyceride concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the curve (AUC) for triglyceride serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Memory and Executive Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of Inhibitors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety and tolerability of intravenous ANX005
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Sight-threatening Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Readmissions rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Reaching the cecum of the colon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of patients enrolled in HIV care who initiate IPT
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of patients who are administered at least 180 doses of IPT within 9 months of IPT initiation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes in depressive symptoms severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Geometric Mean Concentrations (GMCs) of Pneumococcal Immunoglobulin G (IgG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers (GMTs) of Pneumococcal Multiplex Opsonophagocytic Activity (MOPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serotonin transporter activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk-stratification and classification of MM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posttraumatic Stress Diagnostic Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Spasticity and gait disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability measured by ABILOCO scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Participation (quality of life)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants Recovered
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Freezing of Gait (FoG) episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Children satisfaction after surgery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pre-dialysis serum phosphorus levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cessation of tobacco consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Matsuda-DeFronzo Insulin Sensitivity Index (ISI-M)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in ADHD symptoms as measured by CAARS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of NAC treatment in hours
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Presence or absence of focal atheroma and narrowing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: pathologic complete response (ypT0/Tis ypN0)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Occurrence of Any Device and/or Procedure Related Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients With Complete Response to Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of a colectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Children's Yale Brown Obsessive Compulsive Scale (CY-BOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary postoperative ileus (POI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Microvascular bloodflow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Microvascular hemoglobin saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Diurnal IOP Change From Baseline at Week 4 - Study Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10 months-progression free rate (10m-PFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in limb inequality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of peripheral tumor lesions identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean Glucose Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in global and local liver function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety assessment through adverse events monitoring
Endpoint domain: Adverse events/effects
Primary endpoint: serum 25(OH)D changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Composite endpoint of cardiac death, myocardial infarction, and target lesion revascularisation
Endpoint domain: Mortality/survival
Primary endpoint: serum irisin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse event (AE) and serious adverse event (SAE) incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Hospital Anxiety and Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in PANSS-EC Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of febrile neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Modified Rankin score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of patients with improving GFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in central hemodynamic measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tacrolimus plasmatic concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Sitting-induced Pressure Ulcer
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with prostate biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: recurrence of VTE
Endpoint domain: Mortality/survival
Primary endpoint: VTE related death
Endpoint domain: Mortality/survival
Primary endpoint: Delta glucose (maximum rise from baseline glucose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in pelvic floor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Malignant Melanoma (Occurrence Rate)
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants with Non-Small Cell Lung Cancer (Occurrence Rate)
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants with Colon Cancer (Occurrence Rate)
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants with Breast Cancer (Occurrence Rate)
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants with Gastric Cancer (Occurrence Rate)
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Mature Eggs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Carotid Femoral Pulse Wave Velocity (cfPWV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Premature discontinuation rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Disease free survival from first Complete Remission
Endpoint domain: Mortality/survival
Primary endpoint: Magnitude of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUC0-inf) of Pimasertib Following Oral Administration on Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral Bioavailability of Pimasertib After Single Oral Dose of Unlabeled Pimasertib and Intravenous (IV) Single Tracer Dose of [14C] Pimasertib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mass Balance: Amount of Total Radioactivity Recovered Into the Urine and Feces From Time Zero to the Last Sampling Time Point (Ae0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aggressiveness of endometriosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of autism
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: rate of locoregional recurrences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Correct responses to knowledge related questions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Diarrhoeal incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Later food intake (24 hour)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Later food intake (7 days)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in thyroid function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sniff diaphragm thickening fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resting tidal thickening fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biological activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to loss of virological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes